Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.003 AUD | -25.00% | -33.33% | -92.50% |
Apr. 16 | Melodiol Global's Revenue Surges 79% in Q1 | MT |
Apr. 09 | Melodiol Global Health Subsidiary Health House Australia to Launch Medicinal Cannabis Clinic | MT |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 60.85 | 21.76 | 162.4 | 100.6 | 36.72 | 9.458 |
Enterprise Value (EV) 1 | 57.24 | 22.19 | 159.6 | 93.38 | 42 | 18.41 |
P/E ratio | -3.29 x | -1.19 x | -2.17 x | -3.02 x | -0.89 x | -0.11 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 105 x | 6 x | 66.4 x | 16.2 x | 4.12 x | 0.5 x |
EV / Revenue | 99 x | 6.12 x | 65.2 x | 15 x | 4.71 x | 0.97 x |
EV / EBITDA | -3.64 x | -2.32 x | -11.6 x | -3.39 x | -2.51 x | -1.4 x |
EV / FCF | -7.74 x | -2.08 x | -635 x | -8.49 x | -6.13 x | 2.2 x |
FCF Yield | -12.9% | -48% | -0.16% | -11.8% | -16.3% | 45.4% |
Price to Book | 3.67 x | 1.26 x | 11.9 x | 3.62 x | 1.65 x | -2.33 x |
Nbr of stocks (in thousands) | 6,209 | 8,706 | 45,115 | 61,319 | 91,798 | 236,441 |
Reference price 2 | 9.800 | 2.500 | 3.600 | 1.640 | 0.4000 | 0.0400 |
Announcement Date | 3/24/19 | 2/28/20 | 3/9/21 | 2/28/22 | 3/31/23 | 3/28/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 0.5782 | 3.626 | 2.448 | 6.219 | 8.918 | 18.92 |
EBITDA 1 | -15.73 | -9.554 | -13.72 | -27.51 | -16.77 | -13.17 |
EBIT 1 | -15.74 | -9.952 | -14.06 | -28.35 | -19.34 | -15.2 |
Operating Margin | -2,722.93% | -274.44% | -574.43% | -455.94% | -216.91% | -80.32% |
Earnings before Tax (EBT) 1 | -16.85 | -15.34 | -30.78 | -30.03 | -32.78 | -35.52 |
Net income 1 | -16.76 | -15.05 | -30.78 | -30.03 | -32.78 | -52.45 |
Net margin | -2,897.86% | -415.13% | -1,257.46% | -482.92% | -367.59% | -277.18% |
EPS 2 | -2.978 | -2.094 | -1.661 | -0.5424 | -0.4480 | -0.3762 |
Free Cash Flow 1 | -7.396 | -10.65 | -0.2514 | -11 | -6.851 | 8.367 |
FCF margin | -1,279.02% | -293.61% | -10.27% | -176.88% | -76.82% | 44.22% |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 3/24/19 | 2/28/20 | 3/9/21 | 2/28/22 | 3/31/23 | 3/28/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | 0.43 | - | - | 5.28 | 8.95 |
Net Cash position 1 | 3.61 | - | 2.79 | 7.18 | - | - |
Leverage (Debt/EBITDA) | - | -0.0447 x | - | - | -0.3151 x | -0.6798 x |
Free Cash Flow 1 | -7.4 | -10.6 | -0.25 | -11 | -6.85 | 8.37 |
ROE (net income / shareholders' equity) | -89.8% | -91.8% | -201% | -145% | -131% | -390% |
ROA (Net income/ Total Assets) | -44.9% | -27.7% | -42.1% | -73.2% | -35.9% | -33.3% |
Assets 1 | 37.36 | 54.39 | 73.17 | 41.04 | 91.24 | 157.4 |
Book Value Per Share 2 | 2.670 | 1.980 | 0.3000 | 0.4500 | 0.2400 | -0.0200 |
Cash Flow per Share 2 | 1.030 | 0.3200 | 0.1300 | 0.1200 | 0.0200 | 0 |
Capex 1 | 6.73 | 1.92 | 0.04 | 0.45 | 0.34 | 0.31 |
Capex / Sales | 1,163.84% | 53.02% | 1.81% | 7.25% | 3.85% | 1.65% |
Announcement Date | 3/24/19 | 2/28/20 | 3/9/21 | 2/28/22 | 3/31/23 | 3/28/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-92.50% | 1.32M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- ME1 Stock
- Financials Melodiol Global Health Limited